GE Healthcare: Analysis

1808 WordsAug 12, 20148 Pages
GE Healthcare During 2011-2013, GE Healthcare’s profits grew at a compounded annual growth rate of 4.3%, and the company anticipates this strong growth to continue in 2014. GE has improved its healthcare segment margins to 16.7%. Healthcare segment constituted nearly 20% of GE’s $16.2 billion industrial profits in 2013. Strategy: Expanding footprint in the emerging markets that has allowed the company to benefit from the rising healthcare spending from these regions, particularly in Asia-Pacific and Latin America A strong focus on research and innovation Cost reduction activities - headcount reduction and exit from low-margin products Simplification initiatives - de-layering of management structure in Europe and reduction of the…show more content…
The long-term goal is to organize the data in a way that helps clinicians not only determine a patient’s current health status, but predict how it may change over time. Software and application-oriented developments have the potential to make patient data more visual and intuitive for a range of clinicians 2 Jul, 2014 - Last week, GE Healthcare announced that it will open its John F Welch Technology Center in Bangalore for startups with ideas for frugal innovation in the maternity and infant healthcare space, where the number of deaths in India have been high. Precision Medicine offers new ways of diagnosing and treating disease, moving away from a “one size fits all approach’ to treatment, to one that is tailored to suit the needs of different individual patients. Cell Therapy- here are a number of on-going clinical trials for conditions such as macular degeneration, stroke, heart disease and spinal cord injury and GE has a research laboratory in Cardiff which is dedicated to the development of new technologies for cell therapy. Another type of cell therapy is cellular immunotherapy which uses the body’s own immune cells to fight against disease. Take heart cells for the treatment of heart failure in patients. At the moment, while it’s at the small clinical trial stage – to treat perhaps 20 patients at a time – it’s manageable. But imagine trying to treat the 200,000 people in London with heart failure? The challenge

More about GE Healthcare: Analysis

Open Document